We are live on
!
Find out more
PSC
Patient Square Capital Portfolio holdings
AUM
$564M
1-Year Est. Return
261.3%
This Fund
S&P 500
This Quarter
Est. Return
+15.38%
1 Year Est. Return
+261.3%
3 Year Est. Return
+328.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$277M
AUM Growth
+$35.7M
(+15%)
Cap. Flow
+$4.04M
Cap. Flow
% of AUM
1.46%
Top 10 Holdings %
Top 10 Hldgs %
90%
Holding
22
New
3
Increased
3
Reduced
10
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$16.8M |
| 2 |
Insmed
INSM
|
+$2.18M |
| 3 |
Geron
GERN
|
+$1.02M |
| 4 |
CDTX
Cidara Therapeutics
CDTX
|
+$360K |
| 5 |
Allogene Therapeutics
ALLO
|
+$355K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Liquidia Corp
LQDA
|
+$7.44M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$3.41M |
| 3 |
Intellia Therapeutics
NTLA
|
+$1.66M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$1.33M |
| 5 |
EyePoint Inc
EYPT
|
+$892K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$24.1B
| $141M | 50.71% |
12,480,000
| – | – |
|
|
2
Insmed
INSM
$21.3B
| $36.1M | 13.02% |
358,800
+28,550
| +9% | +$2.18M |
|
|
3
argenx
ARGX
$52B
| $16M | 5.76% |
+29,000
| New | +$16.8M |
|
|
4
EyePoint Inc
EYPT
$1.04B
| $12.7M | 4.59% |
1,352,837
-129,140
| -9% | -$892K |
|
|
5
Liquidia Corp
LQDA
$7.46B
| $12.7M | 4.58% |
1,020,000
-502,452
| -33% | -$7.44M |
|
6
Ocular Therapeutix
OCUL
$1.84B
| $7.59M | 2.74% |
817,699
-102,500
| -11% | -$802K |
|
7
Cullinan Oncology
CGEM
$999M
| $6.54M | 2.36% |
868,897
-10,000
| -1% | -$80.4K |
|
8
Kymera Therapeutics
KYMR
$8.25B
| $6.11M | 2.2% |
140,000
-2,201
| -2% | -$75.8K |
|
9
Mirum Pharmaceuticals
MIRM
$6.38B
| $5.77M | 2.08% |
113,462
-2,900
| -2% | -$129K |
|
10
Scholar Rock
SRRK
$5.49B
| $5.45M | 1.97% |
154,000
| – | – |
|
11
Enliven Therapeutics
ELVN
$4.15B
| $4.93M | 1.78% |
245,838
-8,000
| -3% | -$151K |
|
12
Nurix Therapeutics
NRIX
$2.41B
| $4.7M | 1.69% |
412,296
-35,000
| -8% | -$378K |
|
13
Agios Pharmaceuticals
AGIO
$1.82B
| $4.65M | 1.68% |
139,732
| – | – |
|
14
Pharvaris
PHVS
$2.25B
| $4.3M | 1.55% |
244,283
-1,213
| -0.5% | -$19.5K |
|
15
Disc Medicine
IRON
$2.93B
| $3.92M | 1.41% |
74,000
-9,000
| -11% | -$423K |
|
|
16
Allogene Therapeutics
ALLO
$635M
| $2.98M | 1.07% |
2,635,000
+266,814
| +11% | +$355K |
|
|
17
Geron
GERN
$821M
| $1.01M | 0.36% |
+716,000
| New | +$1.02M |
|
|
CDTX
18
DELISTED
Cidara Therapeutics
CDTX
| $731K | 0.26% |
+15,000
| New | +$360K |
|
|
YARW
19
Yarrow Bioscience, Inc. Common Stock
YARW
$22.4M
| $523K | 0.19% |
6,341
+1,200
| +23% | +$78K |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| – | – |
-38,500
| Closed | -$3.41M |
|
|
21
Intellia Therapeutics
NTLA
$1.5B
| – | – |
-232,781
| Closed | -$1.66M |
|
|
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-18,600
| Closed | -$1.33M |
|
Similar funds
TCP
AHSW
KF
KBG
AAS
LC
AMCA
OC
Patient Square Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Patient Square Capital held 22 positions worth $277M, up 15% from $242M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Patient Square Capital's Q2 2025 filing shows 3 new, 3 increased, 10 reduced and 3 closed positions. Its largest new stake was argenx: 29,000 shares worth $16M. The largest sale was Liquidia Corp, an estimated $7.44M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Patient Square Capital's largest Q2 2025 buy was argenx: 29,000 shares worth $16M.
- Patient Square Capital added most to Insmed in Q2 2025, an estimated $2.18M increase.
- Patient Square Capital's biggest Q2 2025 reduction was Liquidia Corp, cutting an estimated $7.44M.
- Patient Square Capital fully exited Blueprint Medicines in Q2 2025, selling an estimated $3.41M.
- Patient Square Capital's ten largest holdings make up 90% of its $277M portfolio in Q2 2025.
- Patient Square Capital opened 3 new positions and closed 3 in Q2 2025.
- Patient Square Capital's portfolio value rose 15% quarter-over-quarter to $277M.
Based on Patient Square Capital's 13F filing for Q2 2025, filed 11 Aug 2025.